ORPHA:268114
RAS-associated autoimmune leukoproliferative disease
Also known as: RALD
Clinical definition (Orphanet)
RAS-associated autoimmune leukoproliferative disease (RALD) is a rare genetic disorder characterized by monocytosis, autoimmune cytopenias, lymphoproliferation, , and hypergammaglobulinemia.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Is anyone studying this?
145
145 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
145 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
128 in the last 10 years · medium confidence · 71th percentile (publications denominator)
Is a treatment being tested?
449
trials for this specific condition
449 interventional trials matched this specific condition name; 174 currently recruiting in our sample.
Data as of 26 July 2026
449 interventional trials — more than 59.2% of diseases in the trials denominator have none at all (151 of 255; this disease is at the 99.4th percentile).
medium confidence · 99.4th percentile (trials denominator)
Do we know what causes it?
Yes — we know a specific gene responsible (KRAS).
GenCC classification: Strong.
Who's working on it?
2,309
Distinct author names in 145 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01
- 02
- 03
- 04
- 05
- 06Rao VK8 papers · 2026
ALPS Unit, Laboratory of Clinical and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD 20892, USA. korao@niaid.nih.gov
Papers in Europe PMC - 07Al-Herz W7 papers · 2026
Department of Pediatrics, Kuwait University , Kuwait City , Kuwait ; Allergy and Clinical Immunology Unit, Department of Pediatrics, Al-Sabah Hospital , Kuwait City , Kuwait.
Papers in Europe PMC - 08
- 09
- 10Oliveira JB7 papers · 2015
Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. oliveirajb@cc.nih.gov
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
449 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04146298·Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
- NCT05815173·Ladarixin With Sotorasib in Advanced NSCLC
- NCT07601048·A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- NCT07656376·Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
- NCT07455617·Study of ABO2102 in KRAS-Mutated Solid Tumors
- NCT07668752·A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
- NCT06625775·Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT06545201·RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
- NCT05398094·Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
- NCT07562581·A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
- NCT07463677·Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT06947811·A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
- NCT07639242·Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
- NCT07198841·IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
- NCT07366866·A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
Observational and natural-history studies
72 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT01280825·The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
- NCT04751396·Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- NCT07557849·Multicentric Database for KRAS Mutant Pancreatic Cancer
- NCT06004349·Autoimmune and Autoinflammatory Genetics Study
- NCT07122882·Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
- NCT05630989·A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
- NCT05007340·ILD-SARDs Registry and Biorepository
- NCT04902807·Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
- NCT03276923·Maternal Autoimmune Disease Research Alliance (MADRA) Registry
- NCT06587828·A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- NCT07249060·Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
- NCT06502015·Biomarkers in Autoimmune Disease of Nervous System
- NCT07198620·A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China
- NCT06449989·Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
- NCT00943514·Natural History of Bronchiectasis
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"RAS-associated autoimmune leukoproliferative disease" OR "ALPS4" OR "NRAS autoimmune lymphoproliferative syndrome" OR "RAS-associated autoimmune leukoproliferative disorder" OR "RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic" OR "autoimmune lymphoproliferative syndrome caused by mutation in NRAS"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"RAS-associated autoimmune leukoproliferative disease" OR "ALPS4" OR "NRAS autoimmune lymphoproliferative syndrome" OR "RAS-associated autoimmune leukoproliferative disorder" OR "RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic" OR "autoimmune lymphoproliferative syndrome caused by mutation in NRAS" OR "KRAS" OR "autoimmune lymphoproliferative syndrome" OR "autoimmune disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 449 interventional · 72 observational · 6 expanded access. Only interventional studies enter the trial headline.
Cross-references (from Mondo): OMIM:614470 UMLS:C2674723
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: RALD
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus